Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C59/40—Unsaturated compounds
  • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
  • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
  • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
  • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
  • C07C69/734—Ethers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/34—One oxygen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/60—Three or more oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems

Definitions

• the present invention relates to new carboxylic acid derivatives, their preparation and use.
• Endothelin is a 21 amino acid peptide that is synthesized and released by vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3.
• endothelin or "ET” means one or all isoforms of endothelin.
• Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. This vasoconstriction is known to be caused by the binding of endothelin to its receptor (Nature, 332, 411-415, 1988; FEBS Letters, 211, 440-444, 1988 and Bioche. Biophys. Res. Commun., I, 868-875, 1988).
• endothelin causes persistent vascular contraction in peripheral, renal, and cerebral blood vessels, which can lead to disease.
• endothelin is involved in a number of diseases. These include: hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's syndrome, cerebral vasospasm, stroke, benign prostatic hypertrophy, atherosclerosis and asthma (J. Vascular Med. Biology 2, 207 (1990), J. Am. Med. Association 264, 2868 (1990), Nature r 114 (1990), N. Engl. J. Med. 322. 205 (1989), N. Engl. J. Med.
• ET A and ET B receptor At least two endothelin receptor subtypes, ET A and ET B receptor, are currently described in the literature (Nature 348, 730 (1990), Nature 3_J 732 (1990)). Accordingly, substances that inhibit the binding of endothelin to the two receptors should antagonize the physiological effects of endothelin and should therefore be valuable pharmaceuticals.
• WO 96/11914 describes carboxylic acid derivatives which, however, bind with a high affinity to the ET A receptor and with a substantially lower affinity to the ET B receptor (so-called ET A -specific antagonists).
• ET A -specific antagonists we refer here to those antagonists whose affinity for the ET A receptor is at least 20 times higher than their affinity for the ET B receptor.
• the task was to provide endothelin receptor antagonists which bind to the ET A and ET B receptors with approximately the same affinity (so-called mixed antagonists).
• the invention relates to carboxylic acid derivatives of the formula I.
• R 1 stands for tetrazole or for a group
• Hydrogen the cation of an alkali metal, the cation of an alkaline earth metal, a physiologically compatible organic ammonium ion such as C1 . -C 4 alkyl ammonium or the ammonium ion;
• R 7 can also be a phenyl radical which can carry one to five halogen atoms and / or one to three of the following radicals: nitro, cyano, C1.-C 4 -alkyl, C 1 -C 4 -haloalkyl, hydroxy, C 1 - C 4 alkoxy, mercapto, C 1 -C 4 alkylthio, amino, NH (C 1 -C 4 alkyl), N (Ci . -C 4 alkyl) 2 ;
• a 5-membered heteroaromatic linked via a nitrogen atom such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which has one or two halogen atoms, or one or two C 1 -C 4 -alkyl or one or two C 1 -C 4 -alkoxy groups can carry.
• R 9 means:
• R 1 can also mean
• R 13 and R 14 may be the same or different and have the following meaning:
• R 13 and R 14 together form a C 4 -C 7 alkylene chain which is closed to form a ring and which can pass through
• C ⁇ _C 4 alkyl substituted and in which an alkylene group can be replaced by oxygen, sulfur or nitrogen such as - (CH2.4-, - (CH 2 ) 5 -r - ( CH 2 ) 6 - ⁇ - ( CH 2 ) 2 - 0- ( CH 2 ) 2 -, - (CH 2 ) 7 -, 5 -CH 2 -S- (CH 2 ) 2 -, -CH 2 -NH- (CH 2 ) 2 -, - (CH 2 ) 2 -N- (CH 2 ) 2-
• R 2 is hydrogen, hydroxy, NH 2 , NH (C1-C4-alkyl), (C 1 -C4 -alkyl) 2 , halogen, -C-C 4 -alkyl, C 2 C 4 alkenyl, C 2 C 4 alkynyl, C ⁇ -C 4 -hydroxyalkyl, C 1 -C 4 -haloalkyl, Ci -C 4 -alkoxy, 0 -C-C 4 -haloalkoxy or -C-C 4 -alkylthioo, or CR 2 is with CR 10 as stated below to a 5- or 6-membered ring linked.
• Z is nitrogen or CR 10 , in which R 10 is hydrogen or C 3 -C 4 -alkyl or CR 10 together with CR 2 or CR J forms a 5- or - Q 6-membered alkylene or alkenylene ring which is replaced by one or two C 1 -C 4 alkyl groups can be substituted and in which one or more methylene groups can be replaced by oxygen, sulfur, -NH or N (C 1 -C 4 alkyl) 2 .
• At least one of the ring members X, Y or Z is nitrogen.
• R 3 is hydrogen, hydroxyl, NH 2 , NH (Ci -C 4 alkyl), N (-C-C 4 alkyl) 2 , halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 -alkynyl, -C-C 4 -haloalkyl, C 1 -C 4 -alkoxy, C ⁇ -C -haloalkoxy, C ⁇ -C 4 -hydroxyalkyl, C 1 -C 4 -alkylthio, or CR 3 is with CR 10 as linked above to form a 5- or 6-membered ring.
• R 4 and R 5 (which may be the same or different):
• Phenyl or naphthyl which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, mercapto, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, Ci -C 4 hydroxyalkyl, C 2 -C 4 alkynyl, Ci -C 4 - haloalkyl, C 1 -C 4 alkoxy, phenoxy, carboxy, C ⁇ -C 4 haloalkoxy, CJ-C, alkylthio, amino, H ⁇ C !
• Bond a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S0 2 -, NH or N-alkyl group are connected to one another;
• R 6 C 3 -C 8 cycloalkyl where these radicals can each be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, cyano, C ⁇ -C 4 alkoxy, C ⁇ -C alkyl, C 2 -C 4 -alkenyl, C 2 -C -alkynyl, C 3 -C 6 -alkenyloxy, C 3 -C 6 -alkynyl-oxy, -C-C -alkylthio, C ⁇ -C 4 -haloalkoxy, -C-C -alkylcarbonyl, Ci -C 4 alkoxycarbonyl, C 3 -Cg alkylcarbonylalkyl, NH (C !
• -C alkyl N (Ci -C 4 alkyl) 2 , or phenyl, which can be mono- or polysubstituted, eg mono- to trisubstituted by halogen, nitro, cyano, C 4 alkyl, C 1 -C 4 haloalkyl, C ⁇ -C 4 alkoxy, C 1 -C 4 -haloalkoxy or C ⁇ -C 4 alkylthio;
• Phenyl or naphthyl each of which can be substituted by one or more of the following radicals: halogen, R 15 , nitro, mercapto, carboxy, cyano, hydroxy, amino, C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 - C 4 -alkynyl, C 3 -C ⁇ -alkenyloxy, C 1 -C 4 -haloalkyl, C 3 -C 6 -alkynyloxy, -C-C 4 -alkylcarbonyl, C1 .
• a five- or six-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom which can carry one to four halogen atoms and / or one or two of the following radicals: C 1 -C 4 alkyl, C 2 -C 4 alkenyl, Ci -C 4 haloalkyl, C 1 -C 4 alkoxy, C ⁇ -C 4 haloalkoxy, C1 . -C 4 alkylthio, phenyl or phenoxy where the phenyl radicals can in turn carry one to five halogen atoms and / or one to 10 three of the following radicals: -C 1 -C 4 -alkyl,
• R 15 C ⁇ _C 4 _alkyl, C 1 _C 4 _alkylthio, Cj.-C 4 alkoxy, which carry one of the following radicals: hydroxy, carboxy, amino, NH (C ⁇ _C 4 _alkyl), N (C ⁇ _C 4 alkyl) 2 , Carboxamide or CON (C 1 -C 4 alkyl) 2 ;
• Q A spacer that corresponds in length to a C 2 -C 4 chain.
• the function of Q is to produce a defined distance between the groups R 6 and W in the compounds of the formula I.
• the distance should be the length of a C 2 -C 4 alkyl chain
• 8- alkylcarbonylalkyl NH (C 1 -C 4 -alkyl), N (-C-C 4 -alkyl) 2 , phenyl, which can be mono- or polysubstituted, for example mono- to trisubstituted by halogen, nitro, Cyano, C ⁇ -C 4 -alkyl, C3.-C 4 -haloalkyl, C ⁇ -C 4 -alkoxy, C ⁇ -C -haloalkoxy or -CC 4 -alkylthio.
• spacer Q is part of a 5-7 membered ring
• An alkali metal is e.g. Lithium, sodium, potassium; 45
• An alkaline earth metal is, for example, calcium, magnesium, barium;
• C 3 -C 8 cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
• C 1 -C 4 haloalkyl can be linear or branched, such as, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl,
• C 1 -C 4 haloalkoxy can be linear or branched, such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoro-ethoxy, 2, 2-difluoroethoxy, 1, 1, 2, 2-tetrafluoroethoxy, 2,2,2-tri- fluoroethoxy, 2 -chloro-1, 1,2-trifluoroethoxy, 2 -fluoroethoxy or pentafluoroethoxy;
• C 1 -C 4 alkyl can be linear or branched, such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl or 2-butyl;
• C 2 -C 4 alkenyl can be linear or branched, such as, for example, ethenyl, 1-propen-3-yl, 1-propen-2-yl, 1-propen-1-yl, 2-methyl-1-propenyl, 1- Butenyl or 2-butenyl;
• C 2 -C 4 alkynyl can be linear or branched, such as, for example, ethynyl, 1-propyn-1-yl, 1-propyn-3-yl, 1-butyn-4-yl or 2-butyn-4-yl;
• C 1 -C 4 -alkoxy can be linear or branched, such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1, 1 -dimethylethoxy;
• C 3 -C 6 alkenyloxy can be linear or branched, such as, for example, allyloxy, 2-buten-1-yloxy or 3-buten-2-yloxy;
• C 1 -C 4 -hydroxyalkyl can be linear or branched, such as hydroxymethyl, 1-hydroxyether-2 -yl,
• C 6 -C 6 alkynyloxy can be linear or branched, such as 2-propin-1-yloxy, 2-butyn-1-yloxy or 3-butyn-2-yloxy;
• C 1 -C 4 alkylthio can be linear or branched, such as, for example, methyl thio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio or 1,1-dimethylethylthio;
• C 1 -C 4 -alkylcarbonyl can be linear or branched, such as acetyl, ethylcarbonyl or 2>-propylcarbonyl;
• C 1 -C 4 alkoxycarbonyl can be linear or branched such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl or n-butoxycarbonyl;
• Cs-Ca alkylcarbonylalkyl can be linear or branched, e.g. 2-0xo-prop-l-yl, 3 -oxo-but-1 -yl or 3 -oxo-but-2 -yl
• Ci-Ca alkyl can be linear or branched, such as Cj . -C 4 alkyl, pentyl, hexyl, heptyl or octyl;
• Halogen is e.g. Fluorine, chlorine, bromine, iodine.
• the invention further relates to those compounds from which the compounds of the formula I can be released (so-called prodrugs).
• prodrugs in which the release takes place under conditions such as those in certain body compartments, e.g. in the stomach, intestines, bloodstream, liver, predominate.
• the compounds and also the intermediates for their preparation can have one or more asymmetrically substituted carbon atoms.
• Such compounds can exist as pure enantiomers or pure diastereomers or as a mixture thereof. Preference is given to using an enantiomerically pure compound as the active ingredient.
• the invention further relates to the use of the abovementioned carboxylic acid derivatives for the production of medicaments, in particular for the production of inhibitors for ET A and ET B receptors.
• the compounds according to the invention are particularly suitable as mixed antagonists as defined at the outset.
• Compounds of general formula III are either known or can e.g. can be synthesized by reducing the corresponding carboxylic acids or their esters, or by other generally known methods.
• Carboxylic acid derivatives of the general formula VI can be prepared by reacting a compound of the formula Via with an alcohol or thiol of the formula VII with acid catalysis.
• R 1 has the meaning given under the general formula I.
• R 16 and R 17 which may be the same or different, each optionally substituted, hydrogen or alkyl, alkenyl, alkynyl, phenyl, naphthyl, cycloalkyl,
• R 18 is hydrogen or alkyl, alkenyl, alkynyl, phenyl, naphthyl, cycloalkyl, each optionally substituted
• R 19 is hydrogen or alkyl, alkenyl, alkynyl, phenyl, naphthyl, cycloalkyl, each optionally substituted
• radicals preferably have the following meaning:
• R 16 and R 17 which may be the same or different,
• R 18 alkyl, phenyl, cycloalkyl each optionally substituted
• R 19 alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, each optionally substituted,
• R 18 alkyl optionally substituted, especially methyl
• the carboxylic acid derivatives of the general formula IV can be prepared by this process by reacting a compound of the formula IVa with an alcohol or thiol of the formula III with acid catalysis
• the compounds IVa and III are mixed in bulk or in a solvent which is inert for this reaction and catalytic amounts of an acid such as, for example, p-toluenesulfonic acid are added.
• inert solvents are methylene chloride, benzene or toluene.
• inert solvents which form an azeotrope with the alcohol R 18 OH are also suitable.
• R 11 is halogen or R 12 -S0 2 -, where R 12 is C ! -C 4 alkyl, -C-C 4 haloalkyl or phenyl can be. Furthermore, at least one of the ring members X or Y or Z is nitrogen.
• the reaction preferably takes place in an inert solvent or diluent with the addition of a suitable base, ie a base which brings about a deprotonation of the intermediate IV, in a temperature range from room temperature to the boiling point of the solvent.
• solvents or diluents are aliphatic, alicyclic and aromatic hydrocarbons, each of which may optionally be chlorinated, such as, for example, hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichlorethylene, Ethers, such as diisopropyl ether, dibutyl ether, methyl tert.
• chlorinated such as, for example, hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichlorethylene
• Ethers such as diisopropyl ether, dibutyl ether, methyl tert
• nitriles such as, for example, acetonitrile and propionitrile
• acid amides such as, for example, dimethylformamide, dimethylacetamide and N-methylpyrrolidone
• sulfoxides and sulfones such as, for example, dimethyl sulfoxide and sulfolane.
• an alkali or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride
• a carbonate such as alkali metal carbonate, e.g. Sodium or potassium carbonate
• an alkali or alkaline earth metal hydroxide such as sodium or potassium hydroxide
• an organometallic compound such as butyllithium or a
• Alkali amide such as lithium diisopropyl amide or lithium amide serve.
• Compounds of the formula I can also be prepared by starting from the corresponding carboxylic acids, ie compounds of the formula I in which R 1 is COOH, and converting them first in the usual manner into an activated form such as an acid halide, an anhydride or Imidazolid transferred and then reacted with a corresponding hydroxyl compound H ⁇ R 7 . This reaction can be carried out in the customary solvents and often requires the addition of a base, the above-mentioned being possible. These two steps can also be simplified, for example, by adding the carboxylic acid to
• compounds of the formula I can also be prepared by starting from the salts of the corresponding carboxylic acids, ie from compounds of the formula I in which R 1 is a group COR and R is OM, where M is an alkali metal cation or can be the equivalent of an alkaline earth metal cation.
• R 1 is a group COR and R is OM
• M is an alkali metal cation or can be the equivalent of an alkaline earth metal cation.
• These salts can be reacted with many compounds of the formula RA, where A is a conventional nucleofugic leaving group, for example halogen such as chlorine, bromine, iodine or aryl or alkylsulfonyl optionally substituted by halogen, alkyl or haloalkyl, such as toluenesulfonyl and methylsulfonyl or one other equivalent leaving group.
• the preparation of the compounds I according to the invention requires the use of generally known protecting group techniques.
• R 6 is 4-hydroxyphenyl
• the hydroxy group can first be protected as benzyl ether, which is then cleaved at a suitable stage in the reaction sequence.
• carboxylic acid derivatives of the general formula I - both as pure enantiomers or pure diastereomers or as a mixture thereof - are preferred, in which the substituents have the following meaning:
• R 2 is hydrogen, hydroxy, halogen, N (C ⁇ -C 4 alkyl) 2, C ! -C 4 -alkyl, C -alkoxy, C 4 alkylthio, Ci-C4 haloalkyl, C 1 -C 4 haloalkoxy, or CR 2 is linked to CR 10 to a 5- or 6-membered ring as indicated below;
• At least one of the ring members X, Y or z is nitrogen.
• R 3 is hydrogen, hydroxy, halogen, N (C ⁇ -C 4 -alkyl) 2 , -C-C 4 -alkyl, C ⁇ -C -alkoxy, C ⁇ -C -alkylthio, Ci -C 4 -haloalkyl,
• C 1 -C 4 - haloalkoxy, or CR 3 is linked to CR 10 to give a 5- or 6-membered ring;
• R 4 and R 5 (which may be the same or different):
• Phenyl or naphthyl which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, mercapto, amino, C 1 -C 4 alkyl, Ci C 4 haloalkyl, carboxy, C 1 -C 4 alkoxy , -C -C haloalkoxy, phenoxy, C 1 -C 4 alkylthio, - NH (C 1 -C 4 alkyl) or N (C : -C 4 alkyl) 2 or
• Phenyl which can be substituted one or more times, for example one to three times by halogen, nitro, cyano, C1 . -C 4 alkyl, -C.-C 4 haloalkyl, C 1 -C 4 alkoxy, C1.-C 4 haloalkoxy or C ⁇ -C 4 alkylthio; or
• Phenyl or naphthyl which are ortho-linked via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S0 2 , NH or N-alkyl group
• R 6 C 3 -C 8 cycloalkyl where these radicals can each be mono- or polysubstituted by: halogen, hydroxyl, mercapto, carboxy, nitro, cyano, C ⁇ -C 4 alkoxy, C ⁇ -C alkyl,
• Phenyl or naphthyl each of which can be substituted by one or more of the following radicals: halogen, R 15 , nitro, mercapto, carboxy, cyano, hydroxy, amino, C ⁇ -C 4 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 alkenyloxy, -C-C 4 haloalkyl, C 3 -C 6 alkynyloxy, C 1 -C alkylcarbonyl, C1 .
• a five- or six-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or acid atom which can carry one to four halogen atoms and / or one or two of the following radicals: C1 . -C 4 alkyl, Ci -C 4 haloalkyl, C 1 -C 4 alkoxy, Ci -C 4 haloalkoxy, C 1 -C 4 alkylthio, phenyl, phenoxy or phenylcarbonyl, the phenyl radicals in turn having one to five halogen atoms and / or can carry one to three of the following radicals: -CC 4 alkyl, C 1 -C haloalkyl, Ci-alkoxy, C 1 -C 4 haloalkoxy and / or C1.-C 4 alkylthio;
• R i5 methyl, ethyl, methoxy or ethoxy which carry one of the following radicals: hydroxy, carboxy, amino, NH (-C 4 -alkyl), N (C 4 -C 4 -alkyl) 2 , carboxamide or CON (C ⁇ _C. Alkyl) 2 ;
• radicals can each be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, Ci -C 4 alkyl thio, C 1 -C 4 haloalkoxy, Ci -C alkoxycarbonyl,
• R 2 trif luormethyl, -C -C alkyl, -C -C 4 alkoxy, -C . -C 4 alkylthio, or CR 2 is linked to CR 10 to a 5- or 6-membered ring as indicated below;
• At least one of the ring members X, Y or Z is nitrogen
• R 3 trifluoromethyl, C ⁇ _-C 4 alkyl, C 1 -C 4 -alkoxy, C alkylthio, or CR 3 is linked with CR 10 as indicated above to form a 5- or 6-membered ring;
• R 4 and R 5 (which may be the same or different):
• Phenyl or naphthyl which can be substituted by one or more of the following radicals: halogen, nitro,
• Phenyl or naphthyl which are linked to one another via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO 2 , NH or N-alkyl group
• R 6 C 5 -C 7 cycloalkyl, where these radicals can each be mono- or polysubstituted by: -CC 4 alkoxy,
• C ! -C 4 alkyl C 1 -C 4 alkylthio, halogen, hydroxy, carboxy, cyano, trifluoromethyl, acetyl or phenyl, which can be substituted one or more times, for example one to three times by halogen, cyano, C ⁇ - C 4 -alkyl, C ⁇ _-C 4 - haloalkyl, C ⁇ -C 4 -alkoxy, C J -C 4 - haloalkoxy or C ! -C 4 alkylthio;
• Phenyl or naphthyl each of which can be substituted by one or more of the following radicals: halogen, R 15 , nitro, mercapto, carboxy, cyano, hydroxy, amino, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, acetyl , C ⁇ -C alkoxycarbonyl, C ⁇ -C 4 -alkoxy, C 4 haloalkoxy, phenoxy, C ⁇ . -C 4 alkylthio, NH (C1 . -C 4 alkyl), N (C 3.
• -C 4 alkyl 2 , dioxomethylene, dioxoethylene or phenyl, which can be mono- or polysubstituted, for example one to three times by halogen, nitro, cyano, C1-C 4 alkyl, C 1 -C 4 haloalkyl, C ⁇ -C 4 -alkoxy, C haloalkoxy or C 1 -C 4 -alkylthio;
• a five- or six-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom which can carry one to four halogen atoms and / or one or two of the following radicals: ⁇ - C *, -alkyl, C ⁇ - C 4 - haloalkyl, C 1 -C 4 alkoxy, trifluoromethoxy, C 1 -C 4 alkyl thio, phenyl or phenoxy, where the phenyl radicals in turn can carry one to five halogen atoms and / or one to three of the following radicals: C ⁇ -C 4 -alkyl, halo-C 4 alkyl, Ci-Cj alkoxy, C ⁇ . -C 4 -haloalkoxy and / or -CC 4 alkyl thio;
• R 15 methoxy or ethoxy which have one of the following radicals:
• radicals in each case may be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, C 1 -C 4 - alkyl, C ⁇ -C 4 -alkoxy, C 4 -Alkylthio, or phenyl, which can be substituted one or more times, for example one to three times by halogen, nitro, cyano, C ⁇ -C 4 alkyl, C x -C 4 - haloalkyl, C 1 -C 4 alkoxy, C ⁇ -C - haloalkoxy or C ! -C 4 alkylthio
• the compounds of the present invention offer new therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarction, chronic heart failure, angina pectoris, acute / chronic renal failure, renal failure, cerebral vasospasm, cerebral ischemia, sub-arachnoid hemorrhage, migraine, asthma, Atherosclerosis, endotoxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty, benign prostate hyperplasia, ischemic and intoxication-related kidney failure or hypertension, metastasis and growth of mesenchymal tumors, contrast agent-induced kidney failure , Pancreatitis, gastrointestinal ulcers.
• the compounds according to the invention partly show. also antaganistic effect on the neurokinin receptor.
• the invention further relates to combination preparations of endothelin receptor antagonists of the formula I and inhibitors of the renin-angiotensin system.
• Inhibitors of renin angiotensin Systems are renin inhibitors, angiotensin II antagonists and especially angiotensin converting enzyme (ACE) inhibitors.
• ACE angiotensin converting enzyme
• Another object of the invention are combination preparation from ß-blockers and the above. Endothelin receptor antagonists and from mixed ACE-neutral endopeptidase (NEP) inhibitors and the above Endothelin receptor antagonists.
• NEP mixed ACE-neutral endopeptidase
• the combination preparations can be used in a single galenic. Form or be presented in spatially separate forms. The application can be carried out simultaneously or at different times.
• the dosage in the combination can be up to the maximum amount of the respective single dose. However, it is also possible to use lower doses than with the individual therapy.
• the ET A or ET B receptor-expressing CHO cells were in DMEM NUT MIX F ⁇ 2 medium (Gibco, No. 21331-020) with 10% fetal calf serum (PAA Laboratories GmbH, Linz, No. A15-022) , 1 mM glutamine (Gibco No. 25030-024), 100 U / ml penicillin and 100 ⁇ g / ml streptoycin (Gibco, Sig a No. P-0781) increased. After 48 hours. the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS for 5 minutes at 37 ° C. The mixture was then neutralized with medium and the cells were collected by centrifugation at 300 ⁇ g.
• the cells were adjusted to a concentration of 10 8 cells / ml buffer (50 mM Tris-HCl buffer, pH 7.4) and then disintegrated by ultrasound (Branson Sonifier 250, 40-70 seconds / constant / output 20). Binding tests
• the membranes were incubated in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM MnCl 2 , 40 ⁇ g / ml bacitracin and 0.2% BSA) in a concentration of 50 ⁇ g Protein suspended per test batch and incubated at 25 ° C with 25 pM 125 J-ET ⁇ (ET A receptor test) or 25 pM 125 J-ET 3 (ET B receptor test) in the presence and absence of test substance.
• the non-specific binding was determined with 10 -7 M ET X.
• test animals were given the test compounds i.v. 30 min before the administration of ET1. injected (1 ml / kg). To determine the ET antagonistic properties, the blood pressure changes in the test animals were compared with those in the control animals.
• mice Male normotonic rats weighing 250-350 g (Sprague Dawley, Janvier) are orally pretreated with the test substances. 80 minutes later, the animals are anesthetized with urethane and the carotid artery (for measuring blood pressure) and the jugular vein (application of big endothelin / endothelin 1) are catheterized.
• big endothelin (20 ⁇ g / kg, Appl. Vol. 0.5 ml / kg) or ET1 (0.3 ⁇ g / kg, Appl. Vol. 0.5 ml / kg) is given intravenously. Blood pressure and heart rate are continuously recorded over 30 minutes. The significant and long-lasting changes in blood pressure are calculated as the area under the curve (AUC). To determine the antagonistic effect of the test substances, the AUC of the substance-treated animals is compared with the AUC of control animals compared.
• the compounds according to the invention can be administered in the usual way orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally). It can also be applied with vapors or sprays through the nasopharynx.
• the dosage depends on the age, condition and weight of the patient and on the type of application.
• the daily dose of active substance is between approximately 0.5 and 50 mg / kg body weight when administered orally and between approximately 0.1 and 10 mg / kg body weight when administered parenterally.
• the new compounds can be used in the usual galenical 15 application forms solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
• the active substances can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al .: Pharmaceutical Technology, Thieme -Verlag, Stuttgart, 25 1991).
• the application forms thus obtained contain the following pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (
• Active ingredient usually in an amount of 0.1 to 90 wt .-%.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Cardiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7804712

Family Applications (1)

Country Status (22)

Families Citing this family (23)

Family Cites Families (6)

• 1996
  • 1996-09-05 DE DE19636046A patent/DE19636046A1/de not_active Withdrawn
• 1997
  • 1997-03-02 US US09/254,137 patent/US6670367B1/en not_active Expired - Fee Related
  • 1997-09-02 JP JP10512203A patent/JP2000517329A/ja active Pending
  • 1997-09-02 AU AU45524/97A patent/AU736414B2/en not_active Ceased
  • 1997-09-02 NZ NZ334548A patent/NZ334548A/xx unknown
  • 1997-09-02 CN CN97199458A patent/CN1236362A/zh active Pending
  • 1997-09-02 IL IL12874397A patent/IL128743A0/xx unknown
  • 1997-09-02 CA CA002265504A patent/CA2265504A1/en not_active Abandoned
  • 1997-09-02 PL PL97331998A patent/PL331998A1/xx unknown
  • 1997-09-02 HU HU0000664A patent/HUP0000664A3/hu unknown
  • 1997-09-02 KR KR1019997001815A patent/KR20000068446A/ko not_active Application Discontinuation
  • 1997-09-02 SK SK259-99A patent/SK25999A3/sk unknown
  • 1997-09-02 WO PCT/EP1997/004688 patent/WO1998009953A2/de not_active Application Discontinuation
  • 1997-09-02 BR BR9711693A patent/BR9711693A/pt not_active IP Right Cessation
  • 1997-09-02 TR TR1999/00486T patent/TR199900486T2/xx unknown
  • 1997-09-02 EP EP97943819A patent/EP0929529A2/de not_active Withdrawn
  • 1997-09-04 ZA ZA977946A patent/ZA977946B/xx unknown
  • 1997-09-04 CO CO97051479A patent/CO4900070A1/es unknown
  • 1997-09-05 AR ARP970104059A patent/AR009543A1/es not_active Application Discontinuation
  • 1997-09-05 ID IDP973110A patent/ID19417A/id unknown
• 1999
  • 1999-03-04 NO NO19991079A patent/NO312674B1/no not_active IP Right Cessation
  • 1999-03-16 BG BG103258A patent/BG103258A/xx unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events